Tigecycline's Spectrum Against Key Bacteria
Tigecycline, a glycylcycline antibiotic, targets multidrug-resistant (MDR) Gram-positive, Gram-negative, and anaerobic bacteria by inhibiting protein synthesis. It shows strong in vitro activity against pathogens like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, and Acinetobacter baumannii. MIC90 values (concentration inhibiting 90% of isolates) are typically ≤2 μg/mL for these, outperforming tetracyclines against resistant strains.[1][2]
Effectiveness Against Common MDR Pathogens
- MRSA and Gram-positives: 95-100% susceptibility in surveillance data; effective for skin/soft tissue infections and complicated intra-abdominal infections (cIAI).[3]
- ESBL-producing E. coli and Klebsiella: >90% susceptibility; FDA-approved for cIAI and complicated skin infections caused by these.[1]
- Carbapenem-resistant Enterobacteriaceae (CRE): Variable, 70-85% susceptibility; useful as salvage therapy but not first-line.[2][4]
- Pseudomonas aeruginosa: Poor activity (MIC90 >8 μg/mL); not reliable.[1]
Clinical trials (e.g., TEST program) confirm bacteriological eradication rates of 80-95% for approved indications.[3]
How Tigecycline Works and Resistance Patterns
It binds 30S ribosomal subunit, evading common efflux pumps and ribosomal protection in resistant bacteria. Resistance emerges via efflux overexpression (e.g., Tet(A)) or mutations, seen in 5-15% of Acinetobacter isolates. Higher doses (100 mg loading, 50 mg BID) improve outcomes in severe infections.[2][4]
Clinical Success Rates in Trials
Phase 3 trials showed non-inferiority to comparators:
| Indication | Tigecycline Cure Rate | Comparator (e.g., Imipenem) |
|------------|-----------------------|-----------------------------|
| cIAI | 86-92% | 87-93% |
| cSSSI | 84-91% | 89-92% |
| HAP/VAP | 68-80% (FDA withdrew approval due to mortality risk) | 74-82% |
Real-world data from >10,000 patients report 70-85% success in polymicrobial MDR infections.[3][5]
Limitations and When It Fails
Bacteriostatic (not bactericidal), so suboptimal for bacteremia or neutropenia (mortality risk 4-5% higher in meta-analyses). Avoid in Proteus, Providencia, or P. aeruginosa infections. Pregnancy category D; dose-adjust in liver failure.[1][4]
Alternatives for Resistant Strains
| Bacteria | Stronger Options |
|----------|------------------|
| CRE | Ceftazidime-avibactam, meropenem-vaborbactam |
| A. baumannii | Colistin, sulbactam |
| MRSA | Vancomycin, daptomycin, linezolid |
Consult local antibiograms for guidance.[2]
Sources
[1]: FDA Tigecycline Label
[2]: Clinical Infectious Diseases Review (2009)
[3]: TEST Surveillance (2010)
[4]: IDSA Guidelines (2024)
[5]: Meta-analysis, Lancet Infect Dis (2014)